Capital Investment Services of America Inc. Has $7.63 Million Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Capital Investment Services of America Inc. lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 13.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 96,141 shares of the life sciences company's stock after purchasing an additional 11,524 shares during the period. Capital Investment Services of America Inc. owned about 0.06% of Illumina worth $7,628,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Fourth Dimension Wealth LLC acquired a new position in shares of Illumina during the fourth quarter worth $40,000. PFS Partners LLC raised its holdings in Illumina by 400.0% in the first quarter. PFS Partners LLC now owns 500 shares of the life sciences company's stock valued at $40,000 after acquiring an additional 400 shares in the last quarter. Assetmark Inc. raised its holdings in Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock valued at $44,000 after acquiring an additional 296 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in Illumina in the fourth quarter valued at $45,000. Finally, Lee Danner & Bass Inc. acquired a new stake in Illumina in the fourth quarter valued at $48,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently issued reports on ILMN. Piper Sandler cut their price target on shares of Illumina from $190.00 to $185.00 and set an "overweight" rating on the stock in a report on Thursday, May 15th. Stephens reiterated an "overweight" rating and set a $105.00 target price on shares of Illumina in a research note on Tuesday, May 20th. Guggenheim lowered their target price on shares of Illumina from $122.00 to $114.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Barclays lowered their target price on shares of Illumina from $100.00 to $77.00 and set an "underweight" rating for the company in a research note on Thursday, April 10th. Finally, Royal Bank of Canada lowered their price target on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a research report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $126.94.

Insider Buying and Selling

In related news, CFO Ankur Dhingra bought 6,100 shares of the firm's stock in a transaction dated Monday, May 12th. The stock was bought at an average cost of $81.21 per share, for a total transaction of $495,381.00. Following the transaction, the chief financial officer now owns 24,906 shares of the company's stock, valued at $2,022,616.26. This represents a 32.44% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 2.60% of the company's stock.

Illumina Stock Performance

ILMN traded down $1.20 during trading on Friday, reaching $86.93. 1,612,726 shares of the company's stock were exchanged, compared to its average volume of 2,282,496. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The business has a 50 day moving average price of $79.08 and a 200 day moving average price of $102.64. The company has a market capitalization of $13.76 billion, a P/E ratio of -11.32, a PEG ratio of 1.60 and a beta of 1.32.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.96 by $0.01. Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. The company had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.03 billion. During the same period last year, the business earned $0.98 earnings per share. The business's revenue was down 1.4% on a year-over-year basis. As a group, analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.